(1) Background: Previous studies, mostly performed in European centers, have shown that in-patient multimodal intensive rehabilitation treatments lasting for two to four weeks can improve both motor and non-motor symptoms of Parkinson’s disease (PD) with long-lasting effects. Here, we ascertain the effects of a similar in-patient program in a U.S. center with a retrospective study in a cohort of 153 patients in the moderately advanced stage of PD. (2) Methods: We compared indices of motor and non-motor functions before and immediately after such treatment and investigated the possible differences between men and women. We used the available records of the Beck Depression Inventory, PDQ39, PD Sleep Scale, Timed Up and Go, Vocal Volume, Voice Handicap, and total UPDRS scores. (3) Results: We found that at the end of treatment, which lasted an average of 14 days, all outcome measures significantly improved independently of sex. (4) Conclusions: These results confirm the previous findings with a similar in-patient approach in European centers. They further suggest that this in-patient treatment is a care model that is feasible in U.S. centers and can provide a more immediate benefit to the motor function and quality of life of patients with moderately advanced PD.
Background/Objectives: We have previously shown that motor and non-motor symptoms of patients with Parkinson’s disease (PD) improved after a two-week in-patient multimodal intensive neurorehabilitation and care (iMINC). This program includes five hours/day for five days/week of multimodal neurorehabilitation and drug adjustments, taking advantage of extensive patient observation. In this study, we ascertained whether the improvements observed after iMINC similarly occurred in patients with and without drug adjustments. Methods: With a retrospective approach, the scores of UPDRS Total and Part III, Beck’s Depression Inventory (BDI), PDQ-39, Parkinson’s Disease Sleep Scale (PDSS), and Vocal Volume before and after two weeks of iMINC were compared in two groups of patients with moderate to advanced PD (H&Y Stage 3–4). In one group, drug adjustment was not necessary (PD no drug adjustment, PDnda, 38 patients), and another group underwent drug changes (PD with drug adjustment, PDda, 93 patients). Scores of all tests were compared using ANOVAs (within subject: before iMINC, after iMINC; between subject: PDda, PDnda). Results: Following iMINC, all outcome measures improved in both groups. Conclusions: Pharmacological adjustment is not the major factor that drives the improvement of motor and non-motor outcome scores following iMINC. These findings suggest that this comprehensive in-patient approach addresses most parkinsonian symptoms and that proper medication status may enhance the positive effects of iMINC.